NFlection Therapeutics Employee Directory

Biotechnology ResearchMassachusetts, United States2-10 Employees

NFlection Therapeutics is a small biotechnology company based in Boston, Massachusetts, focused on developing therapies for neurofibromatosis type 1, immunosuppressant-associated cutaneous squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi. The firm targets disorders driven by abnormal activation of the Ras/Raf/MEK/ERK signaling axis and is pursuing topical MEK inhibitors as a treatment approach. Located in the biotechnology research space, it aims to translate pathway biology into localized therapies for skin and related conditions.

In October 2023, NFlection formed a partnership with Moffitt Cancer Center and Stanford researchers that led to the identification of NFX-179, a compound that can be applied to the skin and shown to prevent the development of cutaneous squamous cell carcinoma in preclinical models. The collaboration reflects ongoing work at the intersection of academic research and therapeutic development for skin-related cancers linked to Ras pathway dysregulation.

Sign up for free to view info

Company overview Email format